Apyx Medical Corporation

NASDAQ:APYX

Medical - Devices

Healthcare
$2.49 -1.90%

-$0.08 today

Market cap
$104.89M
Beta
1.39
P/E (TTM)
-19.0
EPS (TTM)
-$0.22
52W Low $1.59High $5.08

Volume 0.19M

Average 0.18M

APYX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Apyx Medical CorporationNASDAQ: APYX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $2.11M (cash outflow) fell 49.2% year over year, ahead of the -55.1% change in trailing-twelve-month net income. Sequentially, it rose 73.1% from the prior quarter. Over 3 fiscal years it compounded at -21.9% a year.

Context

  • Net income amounted to 21.0% of revenue in FY2025, down 28.0 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$8.49M (-23.5%) for the fiscal year ending Dec 2026, a step up from the -52.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.11M+73.1% QoQ
Last fiscal yearDec 2025
-$11.11M-52.9% YoY
LTMMar 2026
-$9.05M-55.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.2%-2.1%+47.1 pp
1 year-52.9%-23.5%+29.3 pp
3-year CAGR-21.9%-31.4%-9.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(11.11M) USD
Year-over-year change
+52.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How APYX compares with its peers on the latest reported figures

  • APYX's LTM Mar 2026 net income of $9.05M is the 7th largest of the 8 companies compared; the peer median is $32.14M.
  • Its year-over-year change of -55.1% is the lowest of 8, against a peer median of +14.1%.
  • Net income amounts to 16.2% of revenue for APYX, versus a peer median of 104.2%.
APYX Competitors Peer median
Net Income for APYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$26.68B +43056.2%+1.1%519699.0%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$50.14M +11.8%-8.1%145.8%
RCELAVITA Medical, Inc.LTM Mar 2026$45.34M -20.5%+22.1%62.7%
SERASera Prognostics, Inc.LTM Mar 2026$32.14M -2.6%-10.3%56386.0%
VANIVivani Medical, Inc.LTM Mar 2026$27.09M +14.1%+24.2%—
PDEXPro-Dex, Inc.LTM Mar 2026$12M +28.1%+25.2%16.1%
APYXApyx Medical CorporationLTM Mar 2026$9.05M -55.1%-21.9%16.2%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$1.83M +115.2%—1.5%
Peer median (excluding APYX) $32.14M+14.1%+11.6%104.2%

Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(15.2M)(23.28M)(18.85M)(23.56M)(11.11M)
Depreciation & Amortization903K890K692K599K655K
Deferred Income Tax00000
Stock-Based Compensation5.09M6.7M5.11M4.01M2M
Change in Working Capital(1.84M)(5.22M)5.54M(1.25M)(1.59M)
Accounts Receivables(4.9M)1.92M3.97M(2.04M)(1.32M)
Inventory(2.86M)(5.57M)1.46M2.26M(1.07M)
Accounts Payables1.15M67K25K(63K)355K
Other Working Capital4.76M(1.63M)88K(1.41M)446K
Other Non-Cash Items603K628K2.25M2.15M2.04M
Operating Cash Flow(10.45M)(20.28M)(5.25M)(18.05M)(8M)
Capital Expenditures(723K)(1.01M)(533K)(722K)(1.11M)
Acquisitions (Net)195K07.41M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(195K)0(147K)00
Investing Cash Flow(723K)(1.01M)6.73M(722K)(1.11M)
Debt Repayment(238K)(148K)35.04M(20K)(20K)
Common Stock Issued67K365K2.72M7M9.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities195K0(5.59M)(235K)60K
Financing Cash Flow24K217K32.17M6.75M9.58M
Effect of Forex Changes103K395K(191K)113K(466K)
Net Change in Cash(11.05M)(20.68M)33.46M(11.91M)(1K)
Free Cash Flow(11.17M)(21.29M)(5.78M)(18.77M)(9.12M)

Apyx Medical Corporation

NASDAQ:APYX

Intrinsic Alpha fair value

Locked

Current Price

$2.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.